ArticleFrontiers in cellular and infection microbiology2025
Establishment of sensitive sandwich-type chemiluminescence immunoassay for
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Diagnosis of Pemphigoid and Pemphigus: A Comparative Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Invasive pulmonary aspergillosis (IPA) poses significant diagnostic challenges in immunocompromised patients, with galactomannan (GM) detection serving as a key biomarker. Existing Platelia™ GM enzyme-linked immunosorbent assay (ELISA) faces limitations in throughput and turnaround time. Methods: We developed a magnetic bead-based chemiluminescent enzyme immunoassay (CLEIA) for GM detection in serum/bronchoalveolar lavage fluid (BALF). Results: Optimized CLEIA parameters enabled 30-min analysis versus 120-min for ELISA. Validation with 241 clinical specimens demonstrated robust analytical performance: diagnostic thresholds of ≥ 0.20 CLEIA Units for serum and BALF matrices (ROC-AUC 0.87, p<0.0001), analytical sensitivity of 0.50 ng/mL, and precision with ≤14.40% total CV, and no hook effect ≤200 ng/mL. Method comparison against the Platelia ELISA revealed 86.72% overall diagnostic agreement (Cohen's k=0.72), while cross-reactivity analyses indicated specificity limitations exclusively with Discussion: This assay enables 75% processing time reduction with uncompromised diagnostic accuracy, positioning it as a high-throughput alternative for rapid IA screening in high-risk cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.